fbpx

BioArctic AB

BIOAb.ST

$12.93

Closing

▼-7.53%

1D

▼-47.76%

YTD

BIOAb

BBG00HVQ6XJ1

Exchange

Sector

Market cap

$1.15B

Volume

683,318

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$1.15B

Analysts' Rating

BUY

Price Target (Mean)

-

Total Analysts

3

P/E

Operating Margin

-152.16%

Beta

0.13

Revenue Growth

1741.98%

52 week high

$26.66

52 week low

$12.73

Div. Yield

0.00%

EPS Growth

24.08

Company Profile

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer’s disease, Parkinson’s disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company’s pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.